Fairly active in SBIR in its early years and having gone public more or less coincident with the firm's program engagement, AMAG Pharmaceuticals Inc (NASDAQ:AMAG) organized primarily around development of products to treat iron deficiency anemia (IDA) in adult patients. The firm also had a strong presense and portfolio of development-stage assets in women's health and hematology/oncology. In November 2020, the firm was itself acquired by Covis Pharma for a reported amount of $498M and absorbed into the Corvis Pharma Group with senior management remaining in place. Headquartered in Luxembourg with operations in Zug, Switzerland, Covis is specialty pharmaceutical company with a global presense marketing therapeutic for patients with life-threatening conditions and chronic illnesses.